SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
呱瓜瓜
Lv1
50 积分
2023-02-09 加入
最近求助
最近应助
互助留言
Enfortumab vedotin and pembrolizumab as new first-line standard for metastatic urothelial cancer
13天前
已完结
Enfortumab vedotin - antibody drug conjugate for the treatment of urothelial cancer
15天前
已关闭
Enfortumab Vedotin: Antibody drug conjugate for the treatment of locally advanced or metastatic urothelial cancer
15天前
已关闭
Efficacy and Safety of Disitamab Vedotin Combined with Programmed Death-1 Inhibitor for Advanced Urothelial Cancer: A Case-Series Study
15天前
已完结
New paradigms in the second line treatment for advanced and metastatic urothelial carcinoma
16天前
已关闭
Enfortumab vedotin (padcev°) as third, or subsequent, treatment line for urothelial carcinoma
16天前
已关闭
HER2 antibody-cytotoxic drug conjugate is the promising targeted therapy for HER2 overexpressing bladder cancer
16天前
已关闭
Enfortumab vedotin and pembrolizumab as new first-line standard for metastatic urothelial cancer
16天前
已完结
HER2 antibody-cytotoxic drug conjugate is the promising targeted therapy for HER2 overexpressing bladder cancer
16天前
已关闭
Study EV-104: Phase 1 study of intravesical enfortumab vedotin for treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC) (Trial in Progress)
17天前
已完结
没有进行任何应助
DOI错误
13天前
时间太长【积分已退回】
15天前
点赞
15天前
重复求助【积分已退回】
16天前
感谢,点赞
16天前
感谢,点赞
20天前
点赞,感谢
24天前
感谢,点赞
27天前
感谢,点赞
27天前
感谢,点赞
28天前
最近帖子
最近评论
综合讨论
无定形、微晶、力致
28天前
没有发布任何评论